David Kirn - 19 Aug 2026 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Reporting relationship: President and Chief Executive Officer, Director
Issuer ticker: FDMT
Reported as of: 19 Aug 2026
Net transaction value: -$1,088,273
SEC form: 4
Accepted by SEC: 21 Aug 2026, 16:06:38 UTC
Prior SEC filing: 05 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Scott Bizily as Attorney-in-Fact for David Kirn

Key filing fact

David Kirn filed Form 4 for 4D Molecular Therapeutics, Inc. (FDMT) on 21 Aug 2026.

Key facts

This page summarizes David Kirn's Form 4 filing for 4D Molecular Therapeutics, Inc. (FDMT).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 21 Aug 2026, 16:06.

Change

Previous filing in this sequence was filed on 05 Aug 2026.
Current net transaction value: -$1,088,273.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001834021 Primary reporting owner

Kirn David

Relationship: President and Chief Executive Officer, Director
Address: C/O 4D MOLECULAR THERAPEUTICS INC., 5858 HORTON STREET #455, EMERYVILLE
Signature: /s/ Scott Bizily as Attorney-in-Fact for David Kirn
Signature date: 21 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FDMT transaction

Common Stock

Options Exercise

Transaction value
Shares: +50,000
Change %: +5.9%
Price: $4.14^*
Shares after: 894,895
Date: 19 Aug 2026
Ownership: Direct
Footnotes: F1

FDMT transaction

Common Stock

Sale

Transaction value: $662,622
Shares: -43,149
Change %: -4.8%
Price: $15.36
Shares after: 851,746
Date: 19 Aug 2026
Ownership: Direct
Footnotes: F1, F2

FDMT transaction

Common Stock

Sale

Transaction value: $425,651
Shares: -25,927
Change %: -3%
Price: $16.42
Shares after: 825,819
Date: 19 Aug 2026
Ownership: Direct
Footnotes: F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FDMT transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -50,000
Change %: -19%
Price: $0.000000^*
Shares after: 217,500
Date: 19 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $4.14
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

Footnote F2

The transaction was executed in multiple trades in prices ranging from $14.91 to $15.84, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F3

The transaction was executed in multiple trades in prices ranging from $15.97 to $16.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F4

The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

SEC remarks

President and Chief Executive Officer